Thales Hein da Rosa

Thales Hein da Rosa

Auto-generated profile, based on publicly available information

Thales Hein da Rosa

Universidade Federal do Rio Grande do Sul, Porto Alegre (RS), Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2018 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
AMAlexandre Sampaio Moura
Alexandre Sampaio Moura
RSRafael Pereira dos Santos
Rafael Pereira dos Santos
JMJean Misse
Jean Misse
DSDiego Marcos De Souza
Diego Marcos De Souza
FOFernanda Sales De Oliveira
Fernanda Sales De Oliveira
ARAntonio Luiz Ribeiro
Antonio Luiz Ribeiro

13 November 2024 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
TRThales Hein da Rosa
Thales Hein da Rosa
BBBárbara Jonson Bartikoski
Bárbara Jonson Bartikoski
RSRafaela Cavalheiro Do Espírito Santo
Rafaela Cavalheiro Do Espírito Santo
MFMirian Farinon
Mirian Farinon
JSJordana Miranda de Souza Silva
Jordana Miranda de Souza Silva
RXRicardo Machado Xavier
Ricardo Machado Xavier
Background: Sarcopenia is a muscle disease characterized by reduction of muscle strength and muscle mass. In RA, 25.9 to 43.3% of the patients present sarcopenia. The loss of muscle mass observed in RA patients occurs either by activation of catabolic pathways or by inhibition of anabolic pathways. Despite having a list of drugs capable of treating RA inflammation, their effect on muscle is unclear. Our objective was to evaluate the tofacitinib effect on the muscle mass of collagen-induced arthritis (CIA) mice. Methods: CIA was induced in male DBA/1J mice by subcutaneous injection of Type 2 Collagen plus Freund Adjuvant. Animals were randomized into 3 groups: CIA + tofacitinib; CIA + vehicle; and healthy controls. Treatment was administered twice a day, between days 18 and 45 after induction. Clinical score, edema, and body weight were evaluated during the experimental period. After euthanasia, tibiotarsal joints were collected for assessment of disease histopathological score, and tibialis anterior (TA) and gastrocnemius (GA) muscles were weighed to assess muscle mass. Muscle atrophy was evaluated by measurement of TA myofiber cross-sectional area (CSA). Protein expression was evaluated by western blot using GA homogenates. Serum inflammatory markers were evaluated by ELISA. Statistical analysis included ANOVA followed by Tukey’s or with Kruskal-Wallis. The statistical difference was assumed for p < 0.05. Results: Tofacitinib treatment decreased arthritis severity by reducing clinical score, and hind paw edema in comparison with the vehicle group. Tofacitinib showed weight gain, higher TA and GA weights, and increased CSA compared to the vehicle group. On day 45, Tofacitinib presented increased muscle strength compared to the vehicle group, however, no difference was found in muscle fatigue. Pax7 expression was unchanged, while MyoD expression showed an increasing trend, and myogenin expression was significantly increased in Tofacitinib compared to vehicle and control groups. The treatment didn’t modify Murf-1 expression. Tofacitinib mice showed decreased serum levels of TNF and increased IL-6 serum levels. Conclusion: Tofacitinib attenuated muscle loss in arthritic mice, increased muscle weight and muscle CSA. Activation of satellite cell regeneration, based on the increased expression of myogenin, is a potential mechanism involved in tofacitinib action against muscle loss.

15 July 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
TRThales Hein Da Rosa
Thales Hein Da Rosa
SRSterling H. Ramsey
Sterling H. Ramsey
JLJudy J. Lee
Judy J. Lee
NKNatalia Y. Kozlova
Natalia Y. Kozlova
ZZZixuan Zhao
Zixuan Zhao
NBNunzio Bottini
Nunzio Bottini
Protein tyrosine phosphatases (PTPs) receptor type II A (R2A) are negatively regulated through oligomerization upon binding of their extracellular domains to glycosaminoglycans (GAGs) on heparan sulfate proteoglycans (HSPGs). Inactivation of receptor PTP sigma (PTPRS) by HSPGs promotes the aggressive behavior of fibroblast-like synoviocytes (FLS) in rheumatoid arthritis (RA). Blocking the binding of its N-terminal, membrane-distal immunoglobulin-like 1 and 2 (Ig1&2) domains to its GAG ligands on the HSPG syndecan-4 (SDC4) promotes PTPRS activity and reverses the pathogenic phenotype of FLS. The potential for therapeutically leveraging other PTPRS ectodomain regions is, however, unknown. We show targeting the membrane-proximal fibronectin type III-like 9 (Fn9) domain offers a novel avenue to activate PTPRS. We mapped PTPRS Fn9 as the binding site of three antibodies (Abs) (13G5, 22H8, 49F2) and characterized their effects on cells. Despite sharing similar epitopes, we found large differences in the ability of these Abs to regulate PTPRS activity. One of these, 13G5, reduced PTPRS-dependent cell migration, PTPRS co-localization with SDC4, and PTPRS oligomerization. Single-chain variable fragment Abs of 13G5 and 22H8 were similarly effective at activating cellular PTPRS as 13G5. Replacing the entire 13G5 constant region enhanced its binding and cellular activity, indicating the Ab's potency can be optimized via isotype engineering. Treatment of cells with recombinant Fn9 protein acted as a decoy, disrupting PTPRS colocalization with SDC4 and oligomerization, and inhibiting FLS migration. Finally, significant disease mitigation in mice using 13G5-derived Abs suggests a viable strategy for the generation of novel drugs for RA therapy.

12 September 2022
Verified
Conference Paper
Open access
MVMaria Luísa Gasparini Vieira
Maria Luísa Gasparini Vieira
TRThales Hein da Rosa
Thales Hein da Rosa
BBBárbara Johnson Bartikoski
Bárbara Johnson Bartikoski
LSLeonardo Peterson dos Santos
Leonardo Peterson dos Santos
ADAndressa Di Domenico
Andressa Di Domenico
RXRicardo Xavier
Ricardo Xavier

12 September 2022
Verified
Conference Paper
Open access
NSNatália Garcia dos Santos
Natália Garcia dos Santos
Bárbara Jonson BartikoskiBárbara Jonson Bartikoski
Bárbara Jonson Bartikoski
MFMirian Farinon
Mirian Farinon
TRThales Hein da Rosa
Thales Hein da Rosa
RPRenata Ternus Pedó
Renata Ternus Pedó
RXRicardo Xavier
Ricardo Xavier